NASDAQ:ACTU Actuate Therapeutics Q2 2024 Earnings Report $1.37 +0.07 (+5.38%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Actuate Therapeutics EPS ResultsActual EPS-$4.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AActuate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AActuate Therapeutics Announcement DetailsQuarterQ2 2024Date9/24/2024TimeN/AConference Call DateTuesday, September 24, 2024Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Actuate Therapeutics Earnings HeadlinesActuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric NeuroblastomaJune 9, 2026 | markets.businessinsider.comActuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric NeuroblastomaJune 9, 2026 | globenewswire.comHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors. | SmartAsset (Ad)Actuate Therapeutics Reports Positive Survival Outcomes for Elraglusib in Combination with Standard Chemotherapies for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO 2026June 1, 2026 | quiverquant.comQActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic CancerJune 1, 2026 | globenewswire.comActuate Therapeutics Inc.May 25, 2026 | barrons.comSee More Actuate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Actuate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actuate Therapeutics and other key companies, straight to your email. Email Address About Actuate TherapeuticsActuate Therapeutics (NASDAQ:ACTU) (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers. The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors. By inhibiting CDK9, atuveciclib is designed to disrupt transcription-dependent survival pathways in malignant cells. In addition to its CDK9 program, Actuate is advancing preclinical research on a tumor-homing peptide–drug conjugate that aims to selectively deliver cytotoxic payloads to integrin-expressing tumor cells, thereby enhancing therapeutic index and minimizing off-target effects. Since its founding in 2018, Actuate has built its research and development operations in the San Francisco Bay Area, leveraging collaborations with leading academic institutions and contract research organizations. The company’s clinical trials are currently conducted at premier oncology centers across the United States, with plans to expand its geographic footprint into Europe and Asia as its pipeline advances through development milestones. Actuate’s leadership team comprises industry veterans with extensive experience in oncology research, translational science and biopharmaceutical commercialization. By combining deep scientific expertise with a streamlined development strategy, the company aims to rapidly advance its targeted therapies toward clinical proof of concept and ultimately to regulatory approval.View Actuate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
